• ESTABLISHING A LEADER IN CELL-BASED IMMUNOTHERAPIES BUILT ON DECADES OF EXPERTISE IN THE FIELD OF ALLOGENEIC DENDRITIC CELL BIOLOGY

Immunicum is listed on NASDAQ Stockholm under the ticker IMMU

About us

Developing innovative cancer immunotherapies

Immunicum is advancing novel cell-based approaches to treat blood-borne and solid tumors.

Learn more
About

On Monday, November 15, interested shareholders had the chance to meet and talk with Immunicum's CEO Erik Manting and CFO Lotta Ferm at Immunicum's Meet and Greet event in Stockholm. We greatly appreciated the presence and engagement of the attendees and look forward to organizing similar events in the future.

IMG_2077
IMG_2116
IMG_2119
IMG_2122
IMG_2137
IMG_2151
IMG_2181
IMG_2213
IMG_2231
IMG_2234
IMG_2023
IMG_2097

Podcast about cell and gene therapy featuring Immunicum CEO Erik Manting

Latest Corporate presentation

Immunicum Company Presentation

Tweets by @Immunicum